Abbott's (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in every province across Canadavi, in federal plans like Non-Insured Health ...

Abbott, the creator of continuous glucose monitors, launched the new Assist feature at CES 2026. Part of the Libre app, it ...

In early January 2026, Abbott Laboratories unveiled Libre Assist, an AI-powered feature within its Libre app that helps U.S.

Libre Assist 1 uses generative AI to predict how a food choice may affect a person's glucose levels. 2 It then offers ...

Abbott is tapping the spirit of new beginnings for the New Year by unveiling a “gamechanger" feature within the company’s ...

Abbott has launched Libre Assist, a feature within the Libre app designed to help people living with diabetes better understand how the foods they eat affect their glucose levels.

Buy Abbott: defensive compounder with recurring cash flow. Libre diabetes devices drive growth; 2025 guidance reaffirmed.

In third quarter earnings released Wednesday, Abbott Laboratories reported continued soaring sales of its Freestyle Libre diabetes device, a near return-to-normal in its infant formula business, and, ...

ABBOTT PARK, Ill., Sept. 3, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that it has received CE Mark (Conformite Europeenne) for its FreeStyle ® Libre Flash Glucose Monitoring System, a ...

Pharmaceutical and med device giant Abbott (NYSE: ABT) said today that it had received approval from the Food and Drug Administration (FDA) for its next-generation integrated continuous glucose ...